Fate Therapeutics Announces Preclinical Data Presentation of Novel CAR MICA/B Cell-based Cancer Immunotherapy Program at the 2020 ASGCT Annual Meeting…
stemadminIPS Stem CellsNo comments

Program Incorporates New CAR Constructs Designed to Specifically Target the Pan-tumor Associated Stress Proteins MICA and MICB Proprietary Binding Domains Shown to Overcome MICA/B Shedding, a Common Mechanism of Tumor Cell Escape Broadly Observed Across Solid Tumors Exclusive License Agreement with Dana-Farber Cancer Institute covers MICA/B Binding Domains and iPSC-derived CAR MICA/B Cell Products SAN DIEGO, April 28, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the presentation of a new off-the-shelf, iPSC-derived, chimeric antigen receptor (CAR)-targeted cell-based cancer immunotherapy program at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting to be virtually hosted on May 12 15, 2020. The new preclinical program targets MHC class I related proteins A (MICA) and B (MICB), and is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics

Read more
Global Cell Culture Market : Industry Analysis and Forecast (2019-2026) – MR Invasion
stemadminIPS Stem CellsNo comments

Global Cell Culture Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 12% during forecast period. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis. REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/33004/ Utilization of cell cultures has improved to an extent where old small-scale production and handling of cultures decreasing for the growing demand.

Read more
Genespire Secures 16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies – Global Banking And Finance Review
stemadminStem Cell BankingNo comments

Genespire, a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, announced today the successful close of a 16M Series A financing from Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan. The company also announced the appointment of Julia Berretta, Ph.D., as Chief Executive Officer and member of the Board of Directors. Graziano Seghezzi, Managing Partner at Sofinnova Partners, and Lucia Faccio, Ph.D., Partner at Sofinnova Partners, will also join the Board.

Read more
Human Embryonic Stem Cells (HESC) Market Overview, Top Companies, Region, Application and Global Forecast by 2026 – Latest Herald
stemadminEmbryonic Stem CellsNo comments

Vitrolife Global Human Embryonic Stem Cells (HESC) Market Segmentation This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets

Read more

Theme: Illdy.